Clinical Trial Update: Botulinum Toxin and Saliva Management in Tracheotomised Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating botulinum toxin for saliva management in tracheotomised patients with traumatic brain injury has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Botulinum toxin (botulinum toxin)

Snippet

Sponsor: HCA International Limited | Conditions: Traumatic Brain Injury | Phase 2 | Status: WITHDRAWN